Showing 5791-5800 of 7126 results for "".
- It's Official: Venus Concept Completes Merger with Restoration Roboticshttps://practicaldermatology.com/news/its-official-venus-concept-completes-merger-with-restoration-robotics/2460207/Venus Concept Inc. has completed its previously announced merger with Restoration Robotic, Inc., effective November 7, 2019. Following the completion of the merger, Venus Concept completed a $28 million equity financing by EW Healthcare Partners, HealthQuest Capital, SEDCO Capital
- Poll: People Who Developed AD Symptoms as Kids Experience More Severe Symptomshttps://practicaldermatology.com/news/poll-people-who-developed-ad-symptoms-as-kids-experience-more-severe-symptoms/2460206/Individuals who begin experiencing atopic dermatitis (AD) symptoms as children have vastly different patient journeys and experiences than those who began experiencing symptoms as adults, a new survey from Health Union suggests. Of the survey's 400 respondents, there was a nearly 50
- Pinnacle Dermatology Acquires SkinSpeaks Dermatology Clinics in Twin Citieshttps://practicaldermatology.com/news/pinnacle-dermatology-acquires-skinspeaks-dermatology-clinics-in-twin-cities/2460205/Pinnacle Dermatology has acquired SkinSpeaks in the Twin Cities area including locations in Edina, Woodbury, Burnsville, Blaine and Crystal. “We welcome the patients and staff of SkinSpeaks to the Pinnacle Dermatology network of prac
- New AAD/NPF Guidelines Address Care for Pediatric Psoriasishttps://practicaldermatology.com/news/new-aadnpf-guidelines-address-care-for-pediatric-psoriasis/2460204/New guidelines from the American Academy of Dermatology and the National Psoriasis Foundation offer counsel on how to best manage psoriasis and its extracutaneous manifestations in children and adolescents. The
- Cynosure Enters the Muscle Toning Market in Europe, Middle Easthttps://practicaldermatology.com/news/cynosure-enters-the-muscle-toning-market-in-europe-middle-east/2460200/Cynosure, a division of Hologic, is launching StimSure, a non-invasive electromagnetic technology to build and tone muscle in the abdomen, buttocks and thighs, in Europe and the Middle East. CE marked for muscular atrophy, StimSure can be used to strengthen and tighten the abdomina
- Arcutis Biotherapeutics Plans to Initiate Phase 3 Program for ARQ-151 for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-biotherapeutics-plans-to-initiate-phase-3-program-for-arq-151-for-plaque-psoriasis/2460196/Arcutis Biotherapeutics, Inc. plans to initiate its Phase 3 program of ARQ-151 as a potential topical treatment for plaque psoriasis following its End-of-Phase 2 meeting with the FDA. The Company anticipates initiating a Phase 3 clinical trial in the first half of 2020. Frank Watanabe,
- New Indication for Cellfina: Cleared for 5 Years of Benefit for Cellulitehttps://practicaldermatology.com/news/new-indication-for-cellfina-approval-for-5-years-of-benefit-for-cellulite/2460195/The FDA has cleared a new indication statement for Cellfina that shows the benefits of treatment last for five years, an increase from the previous three-year indication. Cellfina from Merz demonstrated five-year improvement in the appearance of cellulite on the buttocks and thighs of adult femal
- FDA Approves Amzeeq Minocycline Foam from Foamixhttps://practicaldermatology.com/news/fda-approves-amzeeq-minocycline-foam-from-foamix/2460194/The FDA has approved Amzeeq (minocycline) topical foam, 4%, from Foamix Pharmaceuticals for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and pediatric patients 9 years of age and older. Amzeeq, formerly known as FMX101, is the first topical minoc
- UCB Presents New Data for Cimzia, Investigational Bimekizumabhttps://practicaldermatology.com/news/ucb-presents-new-data-for-cimzia-investigational-bimekizumab/2460193/Data on the use of UCB’s Cimzia (certolizumab pegol), in psoriasis and psoriatic arthritis (PsA) as well as Phase 2 data for the company’s investigational molecule bimekizumab have been presented at the 28thEuropean Academy of Dermatology and Venereology congress (EADV) in Madrid. Cim
- Data Show Long-term Benefit for Sun Pharma's Ilumyahttps://practicaldermatology.com/news/data-show-long-term-benefit-for-sun-pharmas-ilumya-1/2460189/Long-term follow-up data from ILUMYA® (tildrakizumab-asmn) Phase 3 reSURFACE 1 and 2 trials showed that the significant response rates seen in the initial 52 and 64 weeks, respectively, were maintained over four years for people with moderate-to-severe plaque psoriasis. More than half of